KLK3 and prostate carcinoma: In the present study, we treated prostate cancer patients with an LH-RH analogue and BCL as a first-line CAB therapy and investigated the response rate, as reflected by a decrease in the PSA level, when FLT was administered instead of BCL as a second-line CAB therapy.